Wondering if GSK is actually undervalued or if there's more to the story than recent headlines suggest? You're not alone, and we're about to dive into what those numbers really mean. Despite a slight ...

Diageo (DEO) has considered a multitude of internal and external candidates, including Emma Walmsley, outgoing CEO of GSK ...

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics through its boron chemistry platform, today announced a collaboration agreement with the ...

GSK now owns the global development and commercialisation rights to Empirico's COPD-targeting (siRNA) oligonucleotide, ...

Facing tens of thousands of lawsuits over cancer risks on the popular heartburn drug Zantac, GSK has argued there's "no consistent or reliable evidence" that the medicine causes cancer. But a new ...

The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.

British Big Pharma GSK is welcoming President Donald Trump to the U.K. with a hefty gift: a five-year, $30 billion planned investment in U.S. R&D and manufacturing. The funds are set to be spread ...

Earlier this year, GSK executives explained to Fierce Biotech why they felt the company’s push into oligonucleotides was such a good fit. Now, the British Big Pharma has added further depth to this ...

Not content with getting the first lupus drug to market in the form of the blockbuster Benlysta more than a decade ago, GSK is handing over $300 million in upfront cash for a clinical-stage T-cell ...

GSK and Flagship Pioneering announced a collaboration on Monday morning to discover and develop a portfolio of medicines and vaccines, with a focus on respiratory and immunology therapeutic areas.

GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a ...